Prime Highlights
- Edwards raised full-year 2026 EPS guidance midpoint to $3.00, topping the $2.97 analyst consensus.
- TAVR sales climbed 14.4% to $1.20 billion, led by strong U.S. and international growth.
Key Facts
- Edwards Lifesciences is a global medical device company specialising in heart valve therapies, listed on NYSE as EW.
- Q1 2026 revenue of $1.65 billion beat the $1.60 billion estimate, up 16.7% year-over-year.
Background
Edwards Lifesciences posted stronger-than-expected first-quarter results in early 2026 and raised its full-year guidance, pushing its shares up 4.1% after the announcement.
The medical device company reported adjusted earnings per share of $0.78, beating the analyst estimate of $0.73 by $0.05. Revenue came in at $1.65 billion, above the $1.60 billion forecast and 16.7% higher than the same period last year. On a constant currency basis, sales grew 12.7%.
CEO Bernard Zovighian said the company built on a solid 2025 and delivered another strong quarter, achieving 12.7% sales growth.
Edwards raised its full-year 2026 constant currency sales growth guidance to a range of 9% to 11%, up from the earlier 8% to 10%. The company also lifted its full-year adjusted EPS guidance to $2.95–$3.05, with a midpoint of $3.00 that edges past the analyst consensus of $2.97.
For the second quarter, Edwards projected revenue of $1.66 billion to $1.74 billion, with a midpoint of $1.70 billion slightly above the $1.683 billion consensus. It guided second-quarter adjusted EPS to $0.70–$0.76, with a midpoint of $0.73, which fell slightly short of the $0.75 estimate.
The company’s TAVR segment led growth, with sales rising 14.4% to $1.20 billion. TMTT sales totaled $173 million, whereas the Surgical division posted sales of $276 million, up 10.1% compared to last year. The gross margin was recorded at 78.2%, down from last year’s 78.7%, whereas the operating margin was recorded at 31.
